Chronic kidney disease (CKD) and hypertension are common health problems among childhood cancer survivors with potentially life-threatening sequelae.

A groundbreaking multinational clinical trial, named RESILIENCE, is underway to test a promising new treatment aimed at ...

New DNA test predicts chemotherapy resistance before treatment, potentially sparing patients from ineffective toxic drugs.

Accord shares how cardiovascular risk impacts long-term patient outcomes in cancer care and how many survivors are at an ...

Moleculin Biotech gets US FDA positive feedback on paediatric study plan for Annamycin in children with R/R AML: Houston Saturday, June 21, 2025, 15:00 Hrs [IST] Moleculin Biotech ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Race Oncology announced the successful and safe dosing of the first patient with a ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than ...

As part of the segment, Walter Klemp, Founder, President, CEO and Chairman of Moleculin, discussed the Company's recently announced positive FDA feedback received on the Pediatric Study Plan for ...

The results suggest toxicity may not be as pervasive as previously thought, which argues for more-personalized monitoring.

Anthracyclines are first-line medications in the treatment of cancer, but in 5% of patients their use is associated with severe cardiotoxicity, leading to chronic heart failure.